New York, NY – November 9, 2015 – Press Release – Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented global content and brand management company Genius Brands International, Inc. (the “Company”) in connection with its private offering whereby the Company sold to accredited investors an aggregate of 4,330,000 shares of common stock, par value $0.001 per share and warrants to purchase up to 4,330,000 shares of common stock for a purchase price of $1.00 per share. Genius Brands received $4,330,000 in gross proceeds from the sale of the securities.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Harvey J. Kesner and Tara Guarneri-Ferrara and was assisted by Associate Jennifer Rodriguez.
SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents Dominari Securities, Revere Securities and Pacific Century Securities in $6 Million Initial Public Offering of BUUU Group Limited - August 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents RBW Capital Partners in $11.225 Million Private Placement of Digital Brands Group - August 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Laidlaw & Company and Craft Capital Management in $10 Million Initial Public Offering of Nasus Pharma - August 14, 2025
